Skip to main content
. 2019 Aug 13;47(1):51–60. doi: 10.1007/s00259-019-04452-y

Fig. 1.

Fig. 1

A 61-year-old patient with NSCLC stage IV, referred for staging before nivolumab treatment. While [18F]FDG-PET is unremarkable for both PET/MRI and PET/CT, the contrast-enhanced MRI component of PET/MRI depicts a small brain metastases in the left hippocampus (cyan arrow) that is not visualized on the contrast-enhanced CT component of PET/CT (× 1.5 magnifications in right lower corners), and for which radiation therapy is indicated